CASI Pharmaceuticals delisted from Nasdaq for failure to meet continued-listing standards
CASI Pharmaceuticals, Inc. was removed from listing on the Nasdaq Stock Market. The exchange initiated the delisting under Rule 17 CFR 240.12d2-2(b) because the company's ordinary shares no longer met continued-listing standards. The removal was effective as of the filing date.
Key facts
- CASI Pharmaceuticals delisted from Nasdaq Stock Market LLC
- Removal basis: Rule 17 CFR 240.12d2-2(b) — failure to meet continued-listing standards
- Security removed: ordinary shares
- Form 25-NSE filed June 23, 2026
Why it matters
The delisting removes CASI from public exchange trading and marks an adverse determination by Nasdaq that the company no longer qualified for listing, signaling it did not meet the exchange's minimum financial or operational requirements.
Share
Derived from 25-NSE filed 2026-06-23. Not investment advice. View the source filing on SEC.gov →